Authors
Latest:
New Discovery Enhances Understanding of Colorectal CancerMUSC Hollings Cancer Center researchers discovered a novel mechanism showing how a certain gene mutation can allow tumors to evade detection by the immune system in colorectal cancer patients.
Latest:
Holly Prigerson on Chemotherapy Regimens for Patients With Advanced Gastric CancerHolly G. Prigerson, PhD, professor of Sociology in Medicine, Irving Sherwood Wright Professor in Geriatrics, Joan and Sanford I. Weill Department of Medicine, director, Center for Research on End of Life Care, Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses chemotherapy regimens for patients with advanced gastric cancer.
Latest:
Dr Rugo on the FDA Approval of Inavolisib Plus Palbociclib and Fulvestrant in PIK3CA-Mutated HR+/HER2– Breast CancerHope S. Rugo, MD, discusses the FDA approval of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutated, HR+/HER2– metastatic breast cancer.
Latest:
Dr Rugo on Managing Treatment-Limiting Toxicities in Breast CancerHope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.
Latest:
Guideline Recommendations for CIN ProphylaxisCurrent recommendations by the National Comprehensive Cancer Network on chemotherapy-induced neutropenia prophylaxis, with special considerations for managing patients with cancer during COVID-19.
Latest:
Therapeutic Advances in Prophylaxis Against CINAn overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.
Latest:
Dr Borghaei on Determining Treatments Utilizing Biomarker Testing in NSCLCHossein Borghaei, DO, MS, discusses the importance of determining the most suitable treatment for patients with non–small cell lung cancer through the use of biomarker testing.
Latest:
Emerging Treatments in SCLC: Bispecific AntibodiesExpert panelists weigh in on emerging data from recent presentations on small cell lung cancer, including novel immunotherapy approaches such as bispecific antibodies targeting DLL3 or therapies targeting TIGIT.
Latest:
SCLC: Second-Line Options and Supportive CareKey opinion leaders in thoracic oncology provide insights into second-line treatment for patients with relapsed/refractory small cell lung cancer and comment on the role of trilaciclib in managing cisplatin-associated neutropenia.
Latest:
Future Directions in Treatment of Small Cell Lung CancerPanelists conclude their discussion by commenting on areas of unmet need and sharing personal perspectives on factors that may change clinical practice for SCLC in the future.
Latest:
Dr. Burris on the Integration of Sacituzumab Govitecan in Metastatic TNBCHoward A. “Skip” Burris, III, MD, FASCO, FACP, discusses the integration of sacituzumab govitecan-hziy into the treatment landscape of metastatic triple-negative breast cancer.
Latest:
Future Directions in the Management of Immune ThrombocytopeniaExpert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.
Latest:
Dr. Burris on the Utility of Sacituzumab Govitecan in Metastatic TNBCHoward A. “Skip” Burris, III, MD, FASCO, FACP, discusses the utility of sacituzumab govitecan-hziy in metastatic triple-negative breast cancer.
Latest:
Dr. Burris on the Potential for Novel Checkpoint Inhibitor Combinations in OncologyHoward A. “Skip” Burris, III, MD, FASCO, FACP, discusses the potential of novel combination strategies with checkpoint inhibitors in oncology.
Latest:
Dr. Burris on the Integration of Sacituzumab Govitecan in Metastatic TNBCHoward A. “Skip” Burris, III, MD, FASCO, FACP, discusses the integration of sacituzumab govitecan-hziy into the treatment landscape of metastatic triple-negative breast cancer.
Latest:
The Rise of Oral OncolyticsHoward Cohen, RPh, MS, FASHP, director of oncology pharmacy services, Smilow Cancer Center, Yale New Haven Health, discusses the rise of oral oncolytics in the treatment landscape during the 2018 NCODA Fall Summit.
Latest:
Dr Hochster on the Role of Cooperative Trials in Academic and Community Health Care SettingsHoward S. Hochster, MD, FACP, discusses the role of cooperative group clinical trials in bridging the gap between academic and community cancer centers.
Latest:
Dr Scher on the Importance of Molecular Testing in Prostate CancerHoward I. Scher, MD, discusses the evolution of molecular testing mechanisms in patients with prostate cancer and highlights the importance of making patient-centered decisions based on test results.
Latest:
E-patients: The Genie is Out of the BottleMelissa received a metastatic lung cancer diagnosis just a few weeks after celebrating her 40th birthday. Within hours of hearing her diagnosis from her primary care physician, she started searching the Internet about her disease and what to expect in terms of treatments.
